Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Malaria Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

62 recruiting trials for Malaria. Eligibility criteria explained in plain English.

TrialFinderData lists 62 Malaria clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 4 is the largest group at 27% (10 studies); the largest phase groups are Phase 4: 10, Phase 3: 8, Phase 1: 7, Phase 2: 7.

Research is led by University of Oxford (10), National Institute of Allergy and Infectious Diseases (NIAID) (7), Liverpool School of Tropical Medicine (4), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 5 trials), followed by Tafenoquine, Primaquine.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
62
Total Trials
62
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Track Malaria trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07358910

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure...

Sponsor: Institut Pasteur du CambodgeEnrolling: 100001 location
RECRUITINGPhase 3NCT06666491

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are...

The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.

Sponsor: GlaxoSmithKlineEnrolling: 3004 locations
RECRUITINGNCT06821282

Surveillance of AMR in DRC

This study addresses knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa, focusing on evaluating the feasibility of AMR surveillance and enhancing local...

Sponsor: University of OxfordEnrolling: 2101 location
RECRUITINGPhase 1NCT05911828

A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the...

Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity. Estimates of 247 million...

Sponsor: Zydus Lifesciences LimitedEnrolling: 361 location
RECRUITINGPhase 4NCT05788094

ACT vs CQ With Tafenoquine for P. Vivax Mono-infection

In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of...

Sponsor: Shoklo Malaria Research UnitEnrolling: 6061 location
RECRUITINGNCT05711485

Platelet-Directed Whole Blood Transfusion Strategy for Malaria

Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.

Sponsor: Johns Hopkins Bloomberg School of Public HealthEnrolling: 1322 locations
RECRUITINGPhase 1NCT06607003

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax...

Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020....

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3001 location
RECRUITINGPhase 4NCT06068530

Mass Vaccine and Drug Administration, Bangladesh

This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug...

Sponsor: University of OxfordEnrolling: 100002 locations
RECRUITINGPhase 3NCT06578572

Seasonal R21 Mass Vaccination for Malaria Elimination

This is a cluster randomized trial to determine the impact of seasonal R21/MM mass vaccination (all ages) on malaria transmission and morbidity. Fifty-four villages (30 in The...

Sponsor: London School of Hygiene and Tropical MedicineEnrolling: 162002 locations
RECRUITINGNCT06418256

Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations

Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1005 locations
RECRUITINGPhase 2NCT05750628

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium...

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Sponsor: Novartis PharmaceuticalsEnrolling: 32712 locations
RECRUITINGPhase 4NCT04704999

Southeast Asia Dose Optimization of Tafenoquine

Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the...

Sponsor: University of OxfordEnrolling: 7005 locations
RECRUITINGNCT05934318

L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)

There are few safe, effective, and affordable interventions to improve pregnancy outcomes in low resource settings where the highest rates of poor birth outcomes occur....

Sponsor: Liverpool School of Tropical MedicineEnrolling: 29601 location
RECRUITINGPhase 4NCT06860178

Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a...

Sponsor: EpicentreEnrolling: 400002 locations
RECRUITINGNCT04083508

Vivax Malaria Human Infection Studies in Thailand

This study is a human challenge study to assess the feasibility and safety of controlled human malaria infection (via P. vivax sporozites) in healthy volunteers, and to develop a...

Sponsor: University of OxfordEnrolling: 61 location
RECRUITINGPhase 1NCT07011511

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in...

This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single...

Sponsor: Medicines for Malaria VentureEnrolling: 721 location
RECRUITINGNCT06232954

Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

A cluster-randomized double-blinded control trial will be conducted in Uganda to demonstrate and quantify the protective efficacy (PE) of Mossie-GO, an active spatial repellent...

Sponsor: Africa Power LimitedEnrolling: 56001 location
RECRUITINGPhase 3NCT06962319

Safety of Antimalarials in the FIRst trimEster

The SAFIRE study aims to find effective treatments with acceptable safety for malaria in early pregnancy, a particularly sensitive time for the adverse consequences of malaria in...

Sponsor: Liverpool School of Tropical MedicineEnrolling: 15103 locations
RECRUITINGPhase 4NCT06967519

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low...

Sponsor: Yale UniversityEnrolling: 3802 locations
RECRUITINGNCT07416461

Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease

The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5....

Sponsor: International Vaccine InstituteEnrolling: 100001 location
RECRUITINGNCT02639299

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria...

Background: Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 15001 location
RECRUITINGPhase 3NCT06923592

Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar

The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial...

Sponsor: London School of Hygiene and Tropical MedicineEnrolling: 192002 locations
RECRUITINGPhase 3NCT06148792

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\[s\] it aims to answer...

Sponsor: Menzies School of Health ResearchEnrolling: 10904 locations
RECRUITINGNCT05285735

Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

This study is a prospective observational study in which a female patient who received IV Artesunate while pregnant can volunteer to provide information about her pregnancy and...

Sponsor: Amivas Inc.Enrolling: 251 location
RECRUITINGNCT06529237

Malaria Molecular Surveillance in Mozambique (Phase 2)

Mozambique is among the ten countries with the highest burden of malaria worldwide, with an estimated 10.3 million cases in 2021. Malaria transmission is highly heterogeneous...

Sponsor: Centro de Investigacao em Saude de ManhicaEnrolling: 187501 location
RECRUITINGPhase 1 / Phase 2NCT03375983

Plasmodium Immunotherapy for Advanced Cancers

The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The...

Sponsor: CAS Lamvac Biotech Co., Ltd.Enrolling: 201 location
RECRUITINGNCT05041556

Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine

The ongoing Malaria Vaccine Pilot Evaluation (MVPE) is being conducted in Ghana, Malawi and Kenya through community and sentinel hospital surveillance systems and a series of...

Sponsor: Kintampo Health Research Centre, GhanaEnrolling: 92804 locations
RECRUITINGPhase 2NCT07147400

Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults

This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of...

Sponsor: Serum Institute of India Pvt. Ltd.Enrolling: 12001 location
RECRUITINGPhase 3NCT05690841

FocaL Mass Drug Administration for Vivax Malaria Elimination

FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium...

Sponsor: University of California, San FranciscoEnrolling: 75301 location
RECRUITINGPhase 1NCT06958198

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria...

This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or...

Sponsor: University of OxfordEnrolling: 561 location
RECRUITINGNCT07257965

Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults

This study is a human challenge study to assess the minimum infective mosquito bite dose in a controlled human malaria Infection (via P. vivax sporozites) in healthy volunteers....

Sponsor: University of OxfordEnrolling: 241 location
RECRUITINGNCT06555809

Evaluation of Artesunate in Infants Being Treated for Severe Malaria

This is essentially a laboratory study that is an addendum to an ongoing prospective Phase 4 multicenter observational study titled: "Safety and Efficacy of Artesunate in Pregnant...

Sponsor: Amivas Inc.Enrolling: 151 location
RECRUITINGNCT02471378

Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates

Background: \- Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 74761 location
RECRUITINGPhase 2NCT06879327

Infant Malaria Vaccine Schedule Optimization

The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.

Sponsor: PATHEnrolling: 9642 locations
RECRUITINGNCT01168271

Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early...

Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 150002 locations
RECRUITINGPhase 2NCT07036159

A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months

The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60...

Sponsor: GlaxoSmithKlineEnrolling: 2382 locations
RECRUITINGPhase 4NCT07052162

Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children

Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide. It accounts for half of all malaria...

Sponsor: Curtin UniversityEnrolling: 301 location
RECRUITINGNCT05071079

A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes

The primary objectives of this study are to assess the safety and feasibility of blood-stage controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers...

Sponsor: University of OxfordEnrolling: 481 location
RECRUITINGPhase 1 / Phase 2NCT05478720

DON in Pediatric Cerebral Malaria

The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years...

Sponsor: Douglas Postels, MD, MSEnrolling: 1522 locations
RECRUITINGPhase 4NCT06601712

Post-discharge Malaria Chemoprevention Implementation Trial in Benin

The proposed research aims to conduct implementation trials in Benin, co-designed with national stakeholders, to evaluate different delivery strategies for optimizing health...

Sponsor: Institut de Recherche Clinique du BeninEnrolling: 6482 locations
RECRUITINGPhase 1 / Phase 2NCT04165590

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors. 2) To explore the safe...

Sponsor: CAS Lamvac Biotech Co., Ltd.Enrolling: 601 location
RECRUITINGNCT00001645

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

The purpose of this study is to evaluate, treat and follow patients with parasitic infections. People with a known or suspected parasitic infection who are at least 1 year old...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 8001 location
RECRUITINGPhase 1NCT06862453

Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults

This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine...

Sponsor: Sanaria Inc.Enrolling: 581 location
RECRUITINGPhase 3NCT07082205

Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge

Background and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly...

Sponsor: Liverpool School of Tropical MedicineEnrolling: 3982 locations
RECRUITINGPhase 2NCT07385287

Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults

This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine)...

Sponsor: Sanaria Inc.Enrolling: 1801 location
RECRUITINGPhase 1NCT06171113

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the...

Sponsor: GlaxoSmithKlineEnrolling: 1561 location
RECRUITINGPhase 4NCT07038837

Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission...

This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering...

Sponsor: EpicentreEnrolling: 700001 location
RECRUITINGPhase 1 / Phase 2NCT05790889

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in...

Sponsor: University of OxfordEnrolling: 4801 location
RECRUITINGNCT07389057

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug...

Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT)...

Sponsor: Noguchi Memorial Institute for Medical ResearchEnrolling: 90001 location
RECRUITINGPhase 1NCT06854042

A Study of Oral E1018 in Healthy Adult Participants

The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the...

Sponsor: Eisai Inc.Enrolling: 321 location

Showing 50 of 62 trials.Search all Malaria trials

Frequently Asked Questions

There are currently 62 clinical trials for Malaria, with 62 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Malaria, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Malaria, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.